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Advancements in phosphodiesterase (PDE)-targeted therapies have shown promise in recent years for treating
patients with a variety of autoimmune diseases. This review summarizes the development of PDE4 inhibitors and
the associated literature with a focus on treatments for autoimmune diseases. After the initial investigations of the
prototypic PDE inhibitor, rolipram, more selective inhibitors targeting the PDE4 isozyme have been developed. With
phase II and phase III clinical trials currently underway to evaluate the safety and efficacy of the latest generation of
PDE4 inhibitors, namely apremilast, a new class of treatments may be around the corner for patients suffering from
chronic, autoimmune diseases.
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Our earliest understanding of phosphodiesterase (PDE) in-
hibitors began with a series of publications by Sutherland
and Rall in the 1950s, describing the properties of cyclic ad-
enosine monophosphate (cAMP). Various cellular pathways
and inflammatory responses are mediated by cAMP, an es-
sential intracellular second messenger made up of phospho-
diester bonds. Evidence showed formation of cAMP was
induced by substances such as epinephrine and glucagon,
and the suppression of the enzymes hydrolyzing cAMP, in-
cluding PDEs, by sodium fluoride and caffeine [1,2]. By the
1960s, the role of cyclic nucleotide second messengers, such
as cAMP, in cell signaling and homeostasis was established,
and regulation of this pathway by PDE inhibitors arose as a
field of considerable interest. However, the immunomodu-
latory properties of cAMP and the anti-inflammatory po-
tential of PDE inhibitors were not demonstrated until the
early 1970s [3-5].
Additional research would later demonstrate the ex-
pression of the PDE isoenzyme PDE4 almost exclusively
within inflammatory cells [6]. Inhibition of PDE4 leads to
the reduction of intracellular cAMP levels, and decreases
in T cell and monocyte derived cytokine and chemokines
including tumor necrosis factor (TNF)α [7-11].* Correspondence: neal.kumar@tufts.edu
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reproduction in any medium, provided the orTargeting PDE4 has enormous clinical potential because
it targets a central pathogenic process that bypasses com-
plex antigen receptor-specific immunoregulatory mecha-
nisms. Indeed, selective PDE4 inhibitors have generated
substantial interest as a treatment for several autoimmune
conditions including ankylosing spondylitis, Alzheimer’s
disease, psoriasis, psoriatic arthritis, sarcoidosis, systemic
lupus erythematosus, inflammatory bowel disease, atopic
dermatitis, rheumatoid arthritis, and multiple sclerosis.Mechanism of action
PDEs are a family of enzymes responsible for the hy-
drolysis and subsequent inactivation of cyclic nucleo-
tides, and have been organized into at least 11 families
based on sequence homogeneity, inhibitor sensitivity,
and biochemical properties [12].
Each enzyme within the PDE4 family specifically tar-
gets cAMP for degradation and consists of four subtypes
(PDE4A to PDE4D). These enzymes are located within
brain and immunocompetent cells such as neutrophils,
T lymphocytes, macrophages and eosinophils [13].
PDE4 inhibition results in the accumulation of the
intracellular second messenger cAMP, downstream acti-
vation of protein kinase A (PKA), and subsequent phos-
phorylation of the transcription factor cAMP-response
element binding protein (CREB). Activation of this path-
way modulates gene transcription of numerous cyto-
kines, and results in suppression of TNFα productionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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structive properties [14].
Pharmacokinetics
The newest and most promising of the PDE4 inhibitors,
apremilast, has been evaluated for its pharmacokinetic
properties and disposition following oral administration.
Multiple daily doses showed rapid absorption (Tmax =
2 h) and a moderately long half-life (8.2 h) [15].
A separate study monitored healthy male subjects fol-
lowing a single, 20 mg, oral dose and found that apremilast
was extensively metabolized via multiple pathways, with
unchanged drug representing 45% of the circulating radio-
activity and <7% of the excreted radioactivity. Analysis
of total radioactivity suggests rapid absorption, with
plasma Tmax values also at 2 h. Mean Cmax and area under
the curve (AUC) values in plasma were 333 ng/ml and
1,970 ng*h/ml, respectively. Metabolic clearance of apre-
milast was the major route of elimination with the key me-
tabolites demonstrating at least 50-fold less pharmacologic
activity than apremilast [16].
Man et al. optimized the structures of a series of 3-
(1,3-dioxo-1,3-dihydroisoindol-2-yl)-3-(3,4-dialkoxyphenyl)
propionic acid analogues to enhance PDE4 and TNFα in-
hibitory activity. So far, oral and intravenous administration
of these analogues in female rats has shown good pharma-
cokinetics with low clearance, a moderate volume of distri-
bution, and a 64% oral bioavailability [17].
Adverse effects
PDE4 is also one of the major phosphodiesterase iso-
enzymes expressed in the central nervous system, and
therefore nausea and emesis are common adverse effects
of drug administration [18]. Early PDE4 inhibitors actu-
ally failed in clinical trials due to the high prevalence of
nausea and emesis [19]. Other adverse effects associated
with repeated administration of PDE4 inhibitors include
headache, diarrhea, fatigue, dyspepsia, nasopharyngitis,
and gastroenteritis [20]. Mesenteric vasculitis is a more
worrisome toxicity that may be associated with the PDE4
inhibitors. Studies performed in rodents have demon-
strated medial necrosis of the mesenteric arteries after
administration of the second generation PDE4 inhibitor
cilomilast. However at a meeting convened by the US
Food and Drug Administration (FDA) in 2003 to discuss
cilomilast in phase III studies, the committee unanimously
agreed that the risk of mesenteric vasculitis is not a safety
concern based on human studies [21].
The newer PDE4 inhibitor, apremilast, has been well
tolerated with few side effects in phase I and II studies.
Phase III clinical trials are currently underway and will
provide more insight into its dosing and side effect profile.
The most frequently reported adverse events have been
headache, nausea and pharyngitis (15,34). Researchersused a recognized pharmacophore from the PDE4 in-
hibitors rolipram and roflumilast in the development of
apremilast, and added it to a series of thalidomide analogs
in efforts to optimize activity and reduce side effects clas-
sically seen with earlier PDE4 inhibitors [22].
Rolipram
The discovery of the anti-inflammatory actions of PDE4
inhibitors arose from early studies with the prototypic
PDE4 inhibitor, rolipram. This was the first selective
PDE4 inhibitor investigated, and has been used numerous
times for drug comparator studies [23]. Rolipram was also
studied as an antidepressant several years before the dis-
covery of its potent PDE4 inhibitory activity [24,25]. Des-
pite its potent anti-inflammatory effects in vitro, clinical
trials were associated with unacceptably high rates of
adverse events, specifically nausea and vomiting [26].
Roflumilast
Roflumilast was the first, and currently only drug in the
PDE4 inhibitor class to be FDA approved. In several
countries, this highly selective PDE4 inhibitor is licensed
for oral, once-daily treatment of severe chronic obstruc-
tive pulmonary disease (COPD). In a pooled analysis of
over 6,000 patients receiving roflumilast, higher rates of
diarrhea, weight loss, nausea, headache, back pain, in-
somnia, decreased appetite, and dizziness were reported
as compared to those receiving placebo. However the
overall rate of adverse events was comparable to that
among patients receiving placebo [27].
Pooled results from the pivotal COPD studies M2-124
and M2-125 showed that the weight loss for those in the
roflumilast group was generally small (<3% of baseline
weight) and typically occurred in the first 6 months of
treatment. By the end of the 6 months, almost two-
thirds of the weight loss could be attributed to a reduc-
tion in fat mass [28]. Prior investigations have revealed a
link between PDE4 and lipolysis, possibly through regula-
tion of cAMP pools in human adipocytes and increased
plasma glucagon-like peptide 1 (GLP-1) concentrations
in rats [29,30].
Flavonoids
Many flavonoids have been reported to inhibit PDE4
[31,32], and also demonstrate additional anti-inflammatory
effects through other pathways. For example, in addition
to PDE4 inhibition, the flavonoid dioclein suppresses the
production of the inflammatory mediators interleukin
(IL)-6, TNFα, a chemokine ligand (CXCL)1/KC, CCL2/JE
(monocyte chemotactic protein 1) and nitric oxide (NO),
and acts as a scavenger of reactive oxygen species [33].
Studies on dioclein have also demonstrated a synergistic
anti-inflammatory effect by targeting multiple pathways
[34]. However in contrast to rolipram, dioclein does not
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PDE1, which may lead to unwanted side effects [35].
Psoriasis
Psoriasis is a chronic inflammatory autoimmune disorder
characterized by inflammatory cell infiltration into the
dermis and epidermis accompanied by keratinocyte hyper-
proliferation [36]. Current treatments, including biological
therapies, downregulate cytokine cascades and chemokine
production. While these interventions can be highly effi-
cacious, limitations include side effects, intravenous or
subcutaneous administration, quality control, and produc-
tion costs.
AN-2728 is a topically administered, boron-containing
compound developed for the treatment of psoriasis. This
compound was found to reduce cytokine production,
such as TNFα and interferon (IFN)y, and demonstrated
activity against the PDE4 enzyme [37]. Several clinical
trials of AN-2728 have reported significant effects on
markers of efficacy, such as TNFα, in addition to being
well tolerated [38].
The determination of cytokines in skin homogenates
revealed that both T helper (Th)1 as well as Th2 cyto-
kines are suppressed by PDE4 inhibitors, further proving
its utility in the treatment of T cell mediated diseases,
such as psoriasis [39].
An open-label, single-arm pilot study investigated the
biological and clinical effects of oral apremilast 20 mg
once daily in patients with severe plaque-type psoriasis.
Of the 19 patients enrolled, 17 completed the study. Of
the 19 subjects, 14 (73.7%) showed improvement in their
Psoriasis Area and Severity Index (PASI) scores follow-
ing a 29-day treatment phase. Among these responders,
T cells were reduced by 28.8% and 42.6% in the dermis
and epidermis, respectively. Epidermal thickness was
also reduced by a mean of 20.5% from baseline [15].
More recently, a phase IIb, randomized, multicenter,
placebo-controlled, dose-ranging trial for the treatment of
plaque-type psoriasis with oral apremilast was completed.
Patients were randomly assigned to apremilast 10 mg twice
daily, apremilast 20 mg twice daily, apremilast 30 mg twice
daily, or placebo. By week 16, a 75% improvement in PASI
scores (PASI75) was achieved in 6% (5/88) assigned pla-
cebo, 11% (10/89) assigned apremilast 10 mg, 29% (25/87)
assigned 20 mg, and 41% (36/88) assigned 30 mg. Signifi-
cant differences from placebo were seen with apremilast
20 mg and 30 mg (P <0.0001), but not 10 mg. Reported
adverse events were most frequently mild to moderate and
included nausea, upper respiratory tract infection, diarrhea,
nasopharyngitis, headache, gastroenteritis, and dyspepsia.
Of the eight serious adverse events, none were judged to be
related to apremilast [40].
Currently there are two phase III, double-blind, placebo-
controlled, multicenter trials (ESTEEM 1 (NCT01194219)and ESTEEM2 (NCT01232283)) investigating the use of
oral apremilast 30 mg in adults with moderate to severe
plaque psoriasis. These trials include a 52 week random-
ized, blinded, placebo-controlled phase, with primary end-
points measured at week 16, in addition to a 4-year
extension phase [40].
Psoriatic arthritis
A phase II, multicenter, randomized, double-blind, placebo-
controlled study enrolled 168 subjects with psoriatic arthri-
tis (PsA) during a 12-week treatment phase. Subjects were
randomized to 20 mg apremilast twice daily, apremilast
40 mg once daily, or placebo. After completing the initial
12-week phase, subjects receiving placebo were given a 12-
week course of apremilast. Following the treatment phase
in both groups, subjects participated in a 4-week observa-
tion phase. The primary endpoint was the proportion of
subjects achieving the American College of Rheumatology
criteria for 20% improvement (ACR20) at week 12.
In total, 44% of actively treated patients achieved the
primary endpoint of ACR20 compared with 12% of the
placebo cohort (P <0.001). The study revealed promising
results for the treatment of PsA with oral apremilast, but
was limited by the relatively short duration and unclear
long-term efficacy and safety data. Additionally, the 90%
of subjects enrolled were white and therefore the study
may lack generalizability. Lastly, prior systemic therapy
for PsA may alter the efficacy of apremilast and was not
examined in this study.
The most common adverse events (AEs) were diar-
rhea, nausea, headache, fatigue, and nasopharyngitis with
84.3% of subjects in the treatment phase reporting at
least one AE. However most events were mild to moder-
ate and no clinically relevant laboratory or electrocardio-
graphic abnormalities were reported [41].
Results of this study are encouraging, and phase III clin-
ical trials are currently underway. The efficacy and tolerabil-
ity of apremilast in patients with psoriatic arthritis are now
being studied in four independent phase III studies (PAL-
ACE 1 (NCT01172938), PALACE 2 (NCT01212757), PAL-
ACE 3 (NCT01212770), and PALACE 4 (NCT01307423))
[40]. These studies include both patients who have received
disease-modifying antirheumatic drugs and those who
have not.
Ankylosing spondylitis
Manifestations of ankylosing spondylitis (AS) include
axial and peripheral skeletal inflammation, fat infiltra-
tion, and new bone formation. Therapeutic response
centers on patient-reported outcomes such as pain, mo-
bility and function as well as objective measures such as
inflammation, and new bone formation that can be visu-
alized by magnetic resonance imaging (MRI) and con-
ventional radiography [42-44]. Moreover, the degree of
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fluctuations in biomarkers [45-47].
Recently, updated management guidelines published
by the Assessment of SpondyloArthritis (ASAS) and the
European League Against Rheumatism (EULAR) report
that there is no evidence for the efficacy of disease-
modifying antirheumatic drugs (DMARDs) such as meth-
otrexate and sulfasalazine for the treatment of axial disease,
leaving patients with limited treatment options. The two
classes of drugs that have been shown to reduce the
signs and symptoms of AS include non-steroidal anti-
inflammatory drugs (NSAIDs) and TNFα blockers [48,49].
Nevertheless, at the 2011 ACR meeting, results from a
small pilot study were presented showing that apremilast
may be efficacious in patients with longstanding AS. This
double-blind, placebo controlled phase II unpowered pilot
study included 36 subjects with longstanding AS who had
not sufficiently responded to NSAIDs over 12 weeks. Of
these subjects, 17 received apremilast 30 mg twice daily
compared to 19 who received placebo. The apremilast
group also saw a significant change from baseline (mean
percentage) in levels of receptor activator of nuclear factor
κB (NFκB) ligand (RANKL) and sclerostin [50].
Rheumatoid arthritis
Rheumatoid arthritis (RA) is another chronic, inflamma-
tory autoimmune disease and primarily targets the syn-
ovial tissues of joints. Local production of cytokines and
chemokines leads to leukocyte infiltration, and eventual
erosion of cartilage and bone [51,52]. TNFα has been
shown to promote cytokine and chemokine production,
as well as cellular activation and articular destruction
in RA [53].
Given the pathophysiologic characteristics of RA, a
study was performed to assess the anti-inflammatory
effects of apremilast in human synovial cells collected from
rheumatoid arthritis patients, as well as two murine
models of arthritis. These synovial cells were cultured in
the presence of increasing concentrations of apremilast for
48 h and enzyme-linked immunosorbent assay (ELISA)
was used to analyze spontaneous TNFα production.
Results from this study showed that apremilast led to
a dose-dependent inhibition of spontaneous production
of TNFα from human rheumatoid synovial membrane
cultures. Additionally, both murine models showed a
significant reduction in arthritis clinical scores over a
ten-day treatment period with apremilast. Healthy joint
architecture was also maintained in a dose-dependent
manner. Unlike the first generation PDE4 inhibitor
rolipram, apremilast did not demonstrate any adverse ef-
fects in treatment-naïve mice, possibly due to enhanced
selectivity of apremilast [54].
An interim analysis of the data from a phase II pilot
study investigating the use of apremilast in combinationwith methotrexate reported that the primary endpoint
of ACR20 was not reached [55]. A placebo-controlled
phase II trial using apremilast as monotherapy for RA is
currently underway [56].
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease that can affect a variety of organs and
is predominantly seen in women. Treatment is focused
on controlling symptoms and often involves the use of
corticosteroids and other systemic immunosuppressant
therapies [57,58].
A recent study targeted increased PDE4 activity in
lupus conditions using MRL/lpr mice (a mouse model
developing severe lupus disease). Four groups of female
MRL/lpr mice were injected at 5, 7, 9 and 13 weeks with
one of ethanol, pentoxifylline, denbufylline, or NCS 613
(a novel PDE4 inhibitor). Results showed that both the
survival time and the appearance of proteinuria of NCS
613-treated mice are significantly delayed, both with
P values of 0.005 [59]. While study size was limited, the
results demonstrate potential for the use of PDE4 inhibi-
tors in patients with SLE.
Sarcoidosis
Previous reports have described the use of PDE4 inhibitors
in patients with the systemic inflammatory disease, sarcoid-
osis. While pentoxifylline has been shown to be effective,
use of this drug is limited by associated adverse events [60].
A small study evaluated the use of apremilast in 15
subjects who had failed systemic therapies for sarcoid-
osis. Patients received oral apremilast 20 mg twice daily,
with a reduction to once daily dosing following the onset
of any adverse event. Only two patients needed dosage
reduction due to jitteriness in one patient and nausea in
the other. No further adverse events were reported fol-
lowing this change in dose.
Active lesions were assessed during 12 weeks of ther-
apy with the Sarcoidosis Activity and Severity Index
(SASI) as well as with photographs taken at baseline and
at week 12. Photographs were presented in random order
to three assessors and were scored from 1 to 5 (1 much
better, 5 much worse).
Results showed a significant reduction in SASI indur-
ation scores at weeks 4 and 12. The normalized mean
score given by the assessors after 12 weeks of therapy
was 2/5 (somewhat better after therapy), with good inter-
reader consistency. Of note, three patients developed
significant worsening of their cutaneous lesions within 3 -
months after discontinuation of apremilast [61].
Inflammatory bowel disease
The group of inflammatory conditions affecting the colon
and small bowel known as inflammatory bowel disease
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weeks to months at a time. Both Crohn’s disease and
ulcerative colitis (UC) present with diarrhea, bleeding,
fecal urgency and incontinence, abdominal pain, and fever
caused by inflammation in the gut.
The long-term therapeutic goal for these patients fo-
cuses on inducing and maintaining remission of symptoms
to improve patient quality of life [62]. Existing anti-
inflammatory agents such as 5-aminosalicyclates and other
immunosuppressants have limitations due to adverse drug
reactions, loss of therapeutic response, or lack of response
in some patients [63].
Like many autoimmune diseases, the inflammation in
inflammatory bowel disease (IBD) has been linked to
upregulation of proinflammatory cytokines, such as TNFα,
and nuclear translocation of the proinflammatory transcrip-
tion factor complex NFκB [64]. TNFα is thought to damage
the gut via upregulation of matrix metalloproteinase
(MMP) production by gut myofibroblasts, leading to break-
down of extracellular matrix, tissue damage, and ulcer for-
mation [65]. The quantity of NFκB activation has also been
shown to correlate with the degree of mucosal inflamma-
tion and disease activity, as well as TNFα upregulation.
NFκB activation works in a positive feedback to induce
TNFα, perpetuating further inflammation and disease pro-
cesses [66].
Given the suppression of TNFα and NFκB associated
with a variety of PDE4 inhibitors, two phase III clinical
trials (FACT I and FACT II) were designed. These stud-
ies investigated the safety and efficacy of the PDE4 in-
hibitor, tetomilast, in treating moderately severe UC.
Both studies were multicenter, randomized, double-blind,
placebo-controlled, parallel-arm, dose comparison studies
of tetomilast in subjects with active UC.
Tetomilast was not found to have a significant effect
on individual symptom or sigmoidoscopy scores. How-
ever, there was a trend for tetomilast to improve severity
of rectal bleeding from baseline when compared to pla-
cebo (P = 0.017). By week 8, the efficacy scores had im-
proved for those patients receiving tetomilast (with or
without concomitant 5-aminosalicylic acid) compared to
those on placebo, although these results were not signifi-
cant statistically. One potential reason for the lack of dif-
ference in the therapeutic response may be the very high
placebo response rates seen in patients with IBD. Both 25
and 50 mg of tetomilast were generally well tolerated in
subjects with active UC with no major adverse events [63].
Atopic dermatitis
Atopic dermatitis is a chronic inflammatory disease
characterized by eczematous lesions and intense itching.
Inflammatory infiltrates in these cutaneous lesions con-
sist of T lymphocytes, neutrophils, eosinophils, mono-
cytes, macrophages, and mast cells [67]. High levels ofPDE4 activity are also found in leukocytes of these pa-
tients [68].
A study in Japan looked at the effects of PDE4 inhibi-
tors, cilomilast, roflumilast, and rolipram on induced
dermatitis in mice models. Cilomilast, roflumilast, and
to a lesser extent rolipram, suppressed myeloperoxidase
(MPO) activity, a quantitative index of neutrophils accu-
mulating in skin associated with chronic inflammation.
After 18 days of treatment, cilomilast and roflumilast
showed a 47 and 36% recovery in skin severity score, re-
spectively. This effect was more potent than the 25% re-
covery seen with cyclosporine A, especially in the earlier
stages of treatment [69].
A subsequent study by Harada et al. used the PDE4B
inhibitor, KF66490 to treat induced AD in mouse models.
KF66490 significantly inhibited increases in ear thickness,
IL-4 and IL-1B levels, and proliferation of fibroblasts and
CD3-positive T cells. Compared to the first generation
PDE4 inhibitor, rolipram, KF66490 also produced less
potent emetic effects [70].
More recently, an open-label prospective trial of
apremilast in 16 patients with moderate to severe AD
was conducted to assess the safety, efficacy, and possible
mechanism of action of apremilast in AD. One cohort
consisted of six subjects treated with apremilast 20 mg
twice daily for 3 months, while the second cohort con-
sisted of ten subjects treated with apremilast 30 mg
twice daily for 6 months. Participants in the study were
required to remain on triamcinolone acetonide 0.1% for
2 weeks prior to the start of the study as well as
throughout the trial. Nausea, the most common adverse
event, was rated as mild and improved over the course
of the study in all patients. After 3 months of treatment,
a significant reduction of itch from baseline (VAS) and
improvement in quality of life (assessed via Dermatology
Life Quality Index (DLQI) score) was seen in cohort 1
(P = 0.02 and P = 0.003, respectively), while Eczema Area
and Severity Index (EASI) and quality of life (DLQI)
scores improved in cohort 2 (P = 0.008 and P = 0.01, re-
spectively). At 6 months, statistically significant improve-
ment was seen in all outcomes in cohort 2, including VAS
(P = 0.03), DLQI (P = 0.03), and EASI (P = 0.002) [71].
Alzheimer’s disease
PDE4 inhibitors have also been investigated in the treat-
ment of patients with Alzheimer’s disease. The neuro-
pathological changes seen in Alzheimer’s are closely linked
to chronic inflammation and apoptosis, with elevations of
biomarkers seen even in early stages of disease [72].
Accumulation of amyloid beta (Aβ) peptides has been
shown to produce inflammatory responses [73], activate
the apoptotic pathway [74], inhibit hippocampal synaptic
plasticity, and impair memory [75]. Similar responses
were induced by infusion of aged Ab25-35 into the
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lowing repeated treatment with rolipram. These positive
findings may be at least partially attributed to the block-
ade of inflammatory responses and apoptosis mediated
by cAMP/CREB signaling. In fact, increased levels of
pCREB were reported in the hippocampus following
treatment with rolipram. These results may suggest a
potential role for the use of PDE4 inhibitors in treatment
of memory loss in patients with Alzheimer’s [75].
Multiple sclerosis
The demyelinating autoimmune disease, multiple scler-
osis (MS), has often been studied in animal models by
inducing experimental autoimmune encephalomyelitis
(EAE) in genetically susceptible animals [76]. The EAE
model also mimics the relapsing-remitting presentation
of MS seen in humans.
One study demonstrated a reduction in the clinical signs
of EAE in mice models during the administration of
rolipram. Improvement was seen during both the initial
presentation of disease as well as subsequent relapses [77].
Matrix metalloproteinases (MMPs) are a gene family
of zinc-dependent endopeptidases involved in the pro-
teolytic modeling of the extracellular matrix as well as
the pathogenesis of several autoimmune disorders of the
peripheral and central nervous systems, such as MS [78].
In vitro models have shown that rolipram inhibits NFκB, a
key regulator of inflammatory processes and gene expres-
sion related to EAE and MS, including MMP-9 [79].
When rats primed to EAE were treated with rolipram,
the high levels of NFκB activation in freshly obtained cells
were prevented. Furthermore, inhibition was also seen after
incubation of encephalitogenic cells with rolipram, indicat-
ing that interference with NFκB activation is a direct effect
of the drug. Inhibition of NFκB was also accompanied by a
decrease in MMP-9 gene expression [80].
Conclusions
Advancements in phosphodiesterase-targeted therapies
have shown promise in recent years for treating patients
with a variety of autoimmune diseases. After the initial in-
vestigations of the prototypic PDE inhibitor rolipram, more
selective inhibitors targeting the PDE4 isozyme have been
developed. With phase II and phase III clinical trials cur-
rently underway to evaluate the safety and efficacy of the
latest generation of PDE4 inhibitors, namely apremilast, a
new class of treatments may be around the corner for pa-
tients suffering from chronic, autoimmune diseases.
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